Novocure announced that it has entered into a term loan agreement with an investment fund managed by Pharmakon Advisors LP. The agreement
provides Novocure with up to $100 million of available borrowing capacity. Under the terms of the agreement, Pharmakon will provide $25 million at closing. Up to $75 million of additional funding will be available to the company, at its option, through June 30, 2016. The agreement has a term of 5 years from the initial funding date.